Skip to main content

Payers' Guide

Select Drug Profiles, Payers' Guide

Lartruvo (Olaratumab) a Novel First-Line Treatment Approved for Patients with Advanced Soft-Tissue Sarcoma

Select Drug Profiles, Payers' Guide

Revlimid (Lenalidomide) Receives New Indication for Multiple Myeloma as Maintenance Therapy After Transplantation

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Rubraca (Rucaparib) Second PARP Inhibitor Approved for Patients with Advanced, BRCA-Positive Ovarian Cancer

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Soliqua 100/33 (Insulin Glargine plus Lixisenatide) Receives FDA Approval for Adults with Type 2 Diabetes

Select Drug Profiles, Payers' Guide

Sustol (Granisetron) First Extended-Release 5-HT3 Receptor Antagonist Approved for the Prevention of Acute and Delayed CINV

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Xeljanz XR (Tofacitinib) First Once-Daily Oral JAK Inhibitor Approved for Patients with Rheumatoid Arthritis

Lisa A. Raedler, PhD, RPh

FDA Approvals, FDA Approvals, Drug Updates, Payers' Guide

Innovation Continues to Drive Drug Development, Even as FDA Approvals Drop in 2016

Dalia Buffery, MA, ABD

Select Drug Profiles, Payers' Guide

Xermelo (Telotristat Ethyl), First-in-Class Tryptophan Hydroxylase Inhibitor, Approved for Carcinoid Syndrome Diarrhea

Select Drug Profiles, Payers' Guide

Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia

Lisa A. Raedler, PhD, RPh

Select Drug Profiles, Payers' Guide

Tremfya (Guselkumab), First-in-Class IL-23 Blocker, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis

11
12
13
14
15
16
17

Page 14 of 19
Results 131 - 140 of 185